Ethereum options open interest decreased by 1.73% to $5.77 billion, while 24-hour trading volume reached $655.37 million. Call options dominated both open interest (63.14%) and daily trading volume (59.21%), indicating a stronger accumulated position in calls compared to puts. The most active contracts by volume were October 27 calls around the $2,375-$2,430 strike prices, while the largest open interest was in longer-dated December 2026 calls. This data highlights a call bias in Ethereum options, reflecting traders' preference for bullish or hedging strategies on the asset's price.
Ethereum options data shows open interest at $5.77 billion and a 24-hour volume of $655.37 million. For readers following major cryptocurrencies, 26 rose and 23 fell among 50 assets on Pluang as of Oct 26, 2026 18:21 WIB. Notable movers include VET at Rp119 with 80% sell activity, SAND at Rp856 with 80% sell activity, and AVAX at Rp161.836 with 57% sell activity.
Corxel Pharmaceuticals US and Amanat Acquisition Corp have agreed to merge, creating a publicly traded biopharmaceutical company focused on oral obesity treatments. The deal will raise approximately $377 million, including $300 million from private i...
Eikon Therapeutics presented updated data on EIK1001, a TLR7/8 dual-agonist, combined with pembrolizumab and chemotherapy for stage 4 non-small cell lung cancer (NSCLC) at the 2026 ESMO Congress. The treatment showed a 72% objective response rate and...
Microsoft, Alphabet, and Amazon together represent about 15% of the S&P 500 index. All three tech giants are scheduled to report their quarterly earnings within a two-day span. These earnings reports are highly anticipated as they provide insight int...
Conow, in partnership with Tuya Smart, has introduced the Atlas 6000 AC in Germany, a 6 kWh AC-coupled plug-and-play home battery designed to upgrade existing rooftop solar systems. This battery features AI-driven energy management that optimizes hou...
BioNTech and DualityBio announced that their Phase-3 clinical trial DYNASTY-Breast02 met its primary endpoint, demonstrating a statistically significant but moderate improvement in progression-free survival for Trastuzumab Pamirtecan compared to chem...
